Automated method and apparatus for embryonic stem cell culture

• US 8,815,585 B2
• Filed: 06/30/2008
• Issued: 08/26/2014
• Est. Priority Date: 06/29/2007
• Status: Active Grant

• Current Assignee: FUJIFILM Cellular Dynamics, Inc. (Fujifilm Holdings Corporation)
• Original Assignee: Cellular Dynamics International, Inc. (Fujifilm Holdings Corporation)
• Inventors: Beardsley, Nathaniel, Bergendahl, Veit, Fitzgerald, Megan, Daigh, Christine
• Primary Examiner(s): FALK, ANNE MARIE
• Application Number:
  US12/164,969
• Publication Number:
  US 20090029462A1
• Time in Patent Office: 2,248 Days
• Field of Search: None
• US Class Current: 435/375
• CPC Class Codes: C12M 23/50 Means for positioning or orientating the apparatus C12M41/08 takes precedence
• CPC Class Codes: C12M 33/06 for multiple inoculation or multiple collection of samples
• CPC Class Codes: C12M 33/07 Dosage or metering devices therefore
• CPC Class Codes: C12M 41/48 Automatic or computerized control automatic analysis G01N35/00
• CPC Class Codes: C12N 2501/70 Enzymes
• CPC Class Codes: C12N 2501/999 Small molecules not provided for elsewhere
• CPC Class Codes: C12N 2509/00 Methods for the dissociation of cells, e.g. specific use of enzymes
• CPC Class Codes: C12N 5/0606 Pluripotent embryonic cells, e.g. embryonic stem cells [ES] embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696

Abstract

The invention concerns methods for automated culture of embryonic stem cells (ESCs) such as human ESCs. In some aspects, methods of the invention employ optimized culture media and limited proteolytic treatment of cells to separate cell clusters for expansion. Automated systems for passage and expansion of ESCs are also provided.

Claims

1. A method for automated expansion of pluripotent stem cells comprising:

(a) obtaining a first population of human pluripotent cells in a growth media;

(b) separating the pluripotent cells with an automated separation system;

(c) delivering the separated cells in fresh growth media into a plurality of culture wells;

(d) culturing the pluripotent cells in the growth media in the plurality of culture wells; and

(e) repeating steps b-d one or more times to provide an expanded population of pluripotent cells;

wherein said culturing does not comprise culturing the pluripotent cells in the presence of fibroblast feeder cells or serum and further wherein the automated separation system comprises contacting the first population of pluripotent cells with a proteolytic enzyme, wherein the proteolytic enzyme is trypsin, recombinant trypsin, a trypsin-like protease or TRYPLE.

2. The method of claim 1, wherein the growth media comprises TeSR media.

3. The method of claim 1, wherein the first population of pluripotent cells is comprised on a cell culture plate.

4. The method of claim 3, wherein the cell culture plate comprises a gel matrix.

5. The method of claim 1, wherein the first population of pluripotent cells is about 60%, 70%, 80% or 90% confluent at the time of cell separation.

6. The method of claim 3, wherein delivering the separated cells in fresh growth media comprises seeding the cells in one or more new cell culture plate(s).

7. The method of claim 6, wherein the surface area of the new cell culture plate(s) is between from about 5 to about 35 times greater than the surface area of the plate comprising the first population of pluripotent cells.

8. The method of claim 7, wherein the surface area of the new cell culture plate(s) is between from about 10 to about 35 times greater than the surface area of the plate comprising the first population of pluripotent cells.

9. The method of claim 1, wherein the proteolytic enzyme is a recombinant enzyme.

10. The method of claim 1, wherein the automated separation system comprises:

(i) removing the media from the first pluripotent cell population;

(ii) contacting the pluripotent cells with a proteolytic enzyme; and

(iii) incubating the cells with a proteolytic enzyme to separate cell clusters.

11. The method of claim 10, wherein a defined media comprising a proteolytic enzyme inhibitor and a Rho-associated kinase (ROCK) inhibitor is added to the solution after step (iii).

12. The method of claim 10, wherein the pluripotent cells are incubated with the proteolytic enzyme for from about 2 to about 10 minutes.

13. The method of claim 10, wherein the pluripotent cells are incubated with the proteolytic enzyme at between about 25°

C. and about 40°

C.

14. The method of claim 13, wherein the pluripotent cells are incubated with the proteolytic enzyme at about 37°

C.

15. The method of claim 10, wherein the automated separation system further comprises:

(iv) subjecting the incubated cells to mechanical agitation to further separate cell clusters.

16. The method of claim 15, wherein the mechanical agitation comprises subjecting the pluripotent cells to shear forces or aspiration.

17. A method for automated expansion of pluripotent stem cells comprising:

(a) obtaining a first population of human pluripotent cells in a growth media;

(b) separating the pluripotent cells with an automated separation system;

(c) delivering the separated cells in fresh growth media into a plurality of culture wells;

(d) culturing the pluripotent cells in the growth media in the plurality of culture wells; and

(e) repeating steps b-d one or more times to provide an expanded population of pluripotent cells;

wherein said culturing does not comprise culturing the pluripotent cells in the presence of fibroblast feeder cells or serum and further wherein the fresh growth media comprises an inhibitor of a proteolytic enzyme, wherein the fresh growth media comprises an inhibitor of the proteolytic enzyme used for cell separation, wherein the proteolytic enzyme inhibitor is a trypsin inhibitor.

18. The method of claim 17, wherein the proteolytic enzyme inhibitor is a soybean trypsin inhibitor.

19. The method of claim 18, wherein the fresh growth media comprises about 0.5 mg/ml of soybean trypsin inhibitor.

20. A method for automated expansion of pluripotent stem cells comprising:

(a) obtaining a first population of human pluripotent cells in a growth media;

(b) separating the pluripotent cells with an automated separation system;

(c) delivering the separated cells in fresh growth media into a plurality of culture wells;

(d) culturing the pluripotent cells in the growth media in the plurality of culture wells; and

(e) repeating steps b-d one or more times to provide an expanded population of pluripotent cells;

wherein said culturing does not comprise culturing the pluripotent cells in the presence of fibroblast feeder cells or serum, wherein the growth media comprises a effective amount of a Rho-associated kinase (ROCK) inhibitor, wherein the Rho-associated kinase (ROCK) inhibitor is HA-100 or H-1135.

21. The method of claim 20, wherein the Rho-associated kinase (ROCK) inhibitor is HA-100.

22. The method of claim 21, wherein the HA-100 is present in a concentration of about 10 μ

M.

23. The method of claim 20, wherein the Rho-associated kinase (ROCK) inhibitor is H-1135.

24. The method of claim 23, wherein the H-1135 is present in a concentration of about 1-3 μ

M.

25. A method for automated expansion of pluripotent stem cells comprising:

(a) obtaining a first population of human pluripotent cells in a growth media;

(b) separating the pluripotent cells with an automated separation system;

(c) delivering the separated cells in fresh growth media into a plurality of culture wells;

(d) culturing the pluripotent cells in the growth media in the plurality of culture wells; and

(e) repeating steps b-d one or more times to provide an expanded population of pluripotent cells;

wherein said culturing does not comprise culturing the pluripotent cells in the presence of fibroblast feeder cells or serum and further wherein no or essentially no differentiation occurs in at least 97% of the expanded population of pluripotent cells, and wherein the pluripotent cells are ES cells.

26. The method of claim 25, wherein the growth media comprises TeSR media.

27. The method of claim 25, wherein the first population of pluripotent cells is comprised on a cell culture plate.

28. The method of claim 27, wherein the cell culture plate comprises a gel matrix.

29. A method for automated expansion of pluripotent stem cells comprising:

(a) obtaining a first population of human pluripotent cells in a growth media;

(b) separating the pluripotent cells with an automated separation system;

(c) delivering the separated cells in fresh growth media into a plurality of culture wells;

(d) culturing the pluripotent cells in the growth media in the plurality of culture wells; and

(e) repeating steps b-d one or more times to provide an expanded population of pluripotent cells;

wherein said culturing does not comprise culturing the pluripotent cells in the presence of fibroblast feeder cells or serum wherein the first population of pluripotent cells is comprised on a cell culture plate and further wherein the first population of pluripotent cells is between about 50% and about 99% confluent at the time of cell separation, and wherein the pluripotent cells are ES cells.

30. The method of claim 29, wherein the first population of pluripotent cells is about 60%, 70%, 80% or 90% confluent at the time of cell separation.

31. The method of claim 29, wherein delivering the separated cells in fresh growth media comprises seeding the cells in one or more new cell culture plate(s).

32. The method of claim 31, wherein the surface area of the new cell culture plate(s) is between from about 5 to about 35 times greater than the surface area of the plate comprising the first population of pluripotent cells.

33. The method of claim 32, wherein the surface area of the new cell culture plate(s) is between from about 10 to about 35 times greater than the surface area of the plate comprising the first population of pluripotent cells.

34. A method for automated expansion of pluripotent stem cells comprising:

(a) obtaining a first population of human pluripotent cells in a growth media;

(b) separating the pluripotent cells with an automated separation system;

(c) delivering the separated cells in fresh growth media into a plurality of culture wells;

(d) culturing the pluripotent cells in the growth media in the plurality of culture wells; and

(e) repeating steps b-d one or more times to provide an expanded population of pluripotent cells;

wherein said culturing does not comprise culturing the pluripotent cells in the presence of fibroblast feeder cells or serum and further wherein the automated separation system comprises contacting the first population of pluripotent cells with a proteolytic enzyme, and wherein the pluripotent cells are ES cells.

35. The method of claim 34, wherein the proteolytic enzyme is trypsin.

36. The method of claim 34, wherein the proteolytic enzyme is recombinant trypsin, a trypsin-like proteinase, or TRYPLE.

37. The method of claim 34, wherein the proteolytic enzyme is a recombinant enzyme.

38. The method of claim 34, wherein the fresh growth media comprises an inhibitor of the proteolytic enzyme used for cell separation.

39. The method of claim 34, wherein the automated separation system comprises:

(i) removing the media from the first pluripotent cell population;

(ii) contacting the pluripotent cells with a proteolytic enzyme; and

(iii) incubating the cells with a proteolytic enzyme to separate cell clusters.

40. The method of claim 39, wherein a defined media comprising a proteolytic enzyme inhibitor and a Rho-associated kinase (ROCK) inhibitor is added to the solution after step (iii).

41. The method of claim 34, wherein the pluripotent cells are incubated with the proteolytic enzyme for from about 2 to about 10 minutes.

42. The method of claim 34, wherein the pluripotent cells are incubated with the proteolytic enzyme at between about 25°

C. and about 40°

C.

43. The method of claim 42, wherein the pluripotent cells are incubated with the proteolytic enzyme at about 37°

C.

44. The method of claim 34, wherein the automated separation system further comprises:

(iv) subjecting the incubated cells to mechanical agitation to further separate cell clusters.

45. The method of claim 44, wherein the mechanical agitation comprises subjecting the pluripotent cells to shear forces or aspiration.

46. A method for automated expansion of pluripotent stem cells comprising:

(a) obtaining a first population of human pluripotent cells in a growth media;

(b) separating the pluripotent cells with an automated separation system;

(c) delivering the separated cells in fresh growth media into a plurality of culture wells;

(d) culturing the pluripotent cells in the growth media in the plurality of culture wells; and

(e) repeating steps b-d one or more times to provide an expanded population of pluripotent cells;

wherein said culturing does not comprise culturing the pluripotent cells in the presence of fibroblast feeder cells or serum and further wherein the fresh growth media comprises an inhibitor of a proteolytic enzyme, and wherein the pluripotent cells are ES cells.

47. The method of claim 46, wherein the proteolytic enzyme inhibitor is a trypsin inhibitor.

48. The method of claim 47, wherein the proteolytic enzyme inhibitor is a soybean trypsin inhibitor.

49. The method of claim 48, wherein the fresh growth media comprises about 0.5 mg/ml of soybean trypsin inhibitor.

50. The method of claim 46, further comprising replacing the growth media comprising the proteolytic enzyme inhibitor with a growth media that is essentially free of said inhibitor.

51. A method for automated expansion of pluripotent stem cells comprising:

(a) obtaining a first population of human pluripotent cells in a growth media;

(b) separating the pluripotent cells with an automated separation system;

(c) delivering the separated cells in fresh growth media into a plurality of culture wells;

(d) culturing the pluripotent cells in the growth media in the plurality of culture wells; and

(e) repeating steps b-d one or more times to provide an expanded population of pluripotent cells;

wherein said culturing does not comprise culturing the pluripotent cells in the presence of fibroblast feeder cells or serum and further wherein the separation system is automated by a liquid handler robot, and wherein the pluripotent cells are ES cells.

52. The method of claim 51, wherein the population of pluripotent cells is free or essentially free from non-pluripotent cells.

53. A method for automated expansion of pluripotent stem cells comprising:

(a) obtaining a first population of human pluripotent cells in a growth media;

(b) separating the pluripotent cells with an automated separation system;

(c) delivering the separated cells in fresh growth media into a plurality of culture wells;

(d) culturing the pluripotent cells in the growth media in the plurality of culture wells; and

(e) repeating steps b-d one or more times to provide an expanded population of pluripotent cells;

wherein said culturing does not comprise culturing the pluripotent cells in the presence of fibroblast feeder cells or serum, wherein the population of pluripotent cells is free or essentially free from non-pluripotent cells and further wherein the population of pluripotent cells is human induced pluripotent stem cells.

54. A method for automated expansion of pluripotent stem cells comprising:

(a) obtaining a first population of human pluripotent cells in a growth media;

(b) separating the pluripotent cells with an automated separation system;

(c) delivering the separated cells in fresh growth media into a plurality of culture wells;

(d) culturing the pluripotent cells in the growth media in the plurality of culture wells; and

(e) repeating steps b-d one or more times to provide an expanded population of pluripotent cells;

wherein said culturing does not comprise culturing the pluripotent cells in the presence of fibroblast feeder cells or serum, wherein the growth media comprises a effective amount of a Rho-associated kinase (ROCK) inhibitor, and wherein the pluripotent cells are ES cells.

55. The method of claim 54, wherein the Rho-associated kinase (ROCK) inhibitor is HA-100.

56. The method of claim 55, wherein the HA-100 is present in a concentration of about 10 μ

M.

57. The method of claim 54, wherein the Rho-associated kinase (ROCK) inhibitor is H-1135.

58. The method of claim 57, wherein the H-1135 is present in a concentration of about 1-3 μ

M.